<DOC>
	<DOCNO>NCT02931890</DOCNO>
	<brief_summary>The CRITICS-II trial aim identify optimal preoperative regimen resectable gastric cancer compare three investigational treatment arm : chemotherapy vs. chemotherapy subsequent chemoradiotherapy vs. chemoradiotherapy . The rationale behind trial design base follow concept : - Preoperative treatment associate well patient compliance postoperative regimen - Preoperative treatment increase likelihood disease downsizing/downstaging radical R0 resection - Preoperative paclitaxel/carboplatin-based concurrent chemoradiotherapy DOC chemotherapy effective , feasible safe regimen</brief_summary>
	<brief_title>Multicentric Randomised Trial Resectable Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>TNM 7th ed stage IBIIIC gastric cancer ( histologically proven ) ; tumour bulk stomach may involve gastrooesophageal junction WHO &lt; 2 Age ≥ 18 yr Resectable adenocarcinoma stomach gastrooesophageal junction No prior abdominal radiotherapy Haematology : Hb ≥5.0 mmol/l ; leukocytes≥3.0x109/l , neutrophils ≥1.5x109/l , thrombocytes ≥100x109/l Renal function : serum creatinine ≤1.25x ULN , creatinine clearance ≥ 50 ml/min ( calculate Cockcroft Gault formula ) Liver function : total bilirubin ≤1.5x ULN , alkaline phosphatase ASAT/ALAT ≤ 3x ULN At stag laparoscopy ( mandatory ) obtain biopsy suspect peritoneal lesion and/or substantial free peritoneal fluid pathologically proven tumor negative Written inform consent Expected adequacy followup Caloric intake≥1500 kcal/day , verify dietician registration . caloric intake &lt; 1500 kcal/day bodyweight decrease &gt; 10 % last 6 month &gt; 5 % last month , dietary intervention oral nutritional support enteral tube feed mandatory T1N0 disease ( assessed endoscopic ultrasound ) Distant metastases Inoperable patient ; due technical surgeryrelated factor general condition Previous malignancy , except adequately treat nonmelanoma skin cancer insitu cancer cervix uterus ; case previous malignancy diseasefree period≥5 year , inclusion accept consultation principal investigator Solitary functioning kidney within radiation field Major surgery within 4 week prior study treatment start , lack complete recovery effect major surgery Uncontrolled ( bacterial ) infection Significant concomitant disease prevent safe administration study drug likely interfere study assessment Uncontrolled angina pectoris , cardiac failure clinically significant arrhythmia Continuous use immunosuppressive agent equivalent &gt; 10 mg daily prednison Concurrent use antiviral agent sorivudine chemically related analogue , brivudine Neurotoxicity &gt; CTC grade 1 Pregnancy breast feeding Patients ( M/F ) reproductive potential implementing adequate contraceptive measure Gastric gastroesophageal stent within radiation field</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>gastric cancer</keyword>
	<keyword>radiotherapy</keyword>
	<keyword>chemoradiotherapy</keyword>
</DOC>